Publications by authors named "Kimberly Pasley"
Article Synopsis
- Research on the effects of new cystic fibrosis treatments (ETI) on mental health shows mixed results, with some studies indicating improvements in mood and others finding no causal link.
- A study involving 81 pediatric cystic fibrosis patients used various questionnaires to assess depression and anxiety symptoms over the first 18 months after starting ETI.
- Findings reveal that most participants had normal mental health symptoms at the start, and those with elevated symptoms experienced significant improvements, with very few reporting severe depression or anxiety by the study's end.
Introduction: The diagnosis of cystic fibrosis (CF) can impact the mental health of caregivers. This study aimed to explore prevalence of postpartum depression (PPD) symptoms in caregivers of infants with CF or CFTR-related metabolic syndrome (CRMS).
Methods: This prospective, observational study was conducted in a CF clinic at a tertiary hospital over 4 years.
Background: With elexacaftor/tezacaftor/ivacaftor (ETI), children with cystic fibrosis (CwCF) are living healthier lives with a focus on typical developmental issues such as attention deficit/hyperactivity disorder (ADHD). This paper characterizes CwCF with ADHD within the first year of ETI treatment.
Methods: This retrospective, observational analysis examines a subgroup of CwCF participating in a longitudinal study obtaining prospective data regarding the impact of ETI on mental health.
Rationale: Limited published research is available on the impact of elexacaftor/tezacaftor/ivacaftor (ETI) beyond the initial few months postdrug initiation, especially for those who initiated therapy via individual investigational new drug application. The experiences of patients with cystic fibrosis (CF) experiencing severe lung disease were reviewed for significant improvements in clinical symptoms and quality of life.
Objectives: To examine clinical outcomes 2 years post-ETI in patients with CF and advanced lung disease.
Background: Cystic Fibrosis (CF) and autism spectrum disorder (ASD) are life-long conditions with intense treatment burdens for patients and families. Patients with a concurrent diagnosis (CF-ASD) experience unique obstacles to CF care. This study describes the experiences of our multidisciplinary CF team in caring for patients with CF-ASD and provides insight into provider and parental perspectives on clinical management.
View Article and Find Full Text PDF